ARDEA BIOSCIENCES (RDEA) rated Outperform by Boenning & Scattergood
Boenning & Scattergood rated Outperform ARDEA BIOSCIENCES (NASDAQ: RDEA) on 05/31/2011, when the stock price was $24.75. Since
then, ARDEA BIOSCIENCES has gained 29.13% as of 06/19/2012's recent price of $31.96. If you would have followed this Boenning & Scattergood's recommendation on RDEA, you would have gained 29.13% of your investment in 385 days.
Ardea Biosciences, Inc. is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of human immunodeficiency virus (HIV), cancer and inflammatory diseases, including gout. The Company's portfolio of product candidates include RDEA806 and 2nd generation non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV indication; RDEA594 for gout; RDEA119 for cancer; RDEA119 for inflammation, and mitogen-activated ERK kinase (MEK) inhibitor for cancer/inflammation.
Our equity research team concentrates on companies that aren’t widely covered in sectors such as water distribution/equipment/technology, financial services, business services, aerospace & defense technology, medical technology and retail.